Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Solve Therapeutics has raised $120.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2025.
Solve Therapeutics's investors include General Atlantic, B Capital, Yosemite, Merck, Abingworth.
Solve Therapeutics is headquartered in Belmont, United States.
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Solve Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Solve Therapeutics — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/solve-therapeutics-belmont-2. Accessed October 21, 2026.
VCBacked. (2025). Solve Therapeutics — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/solve-therapeutics-belmont-2
{{cite web |title=Solve Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/solve-therapeutics-belmont-2 |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated